/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. The BioHub - by Avetix
  2. Episode 250 - Dr. Garry Pairaudeau, Co-Founder CEO & Dr. Anthony Bradley, Co-Founder CSO of Dalton Therapeutics.
Episode 250 - Dr. Garry Pairaudeau, Co-Founder CEO & Dr. Anthony Bradley, Co-Founder CSO of Dalton Therapeutics.

Episode 250 - Dr. Garry Pairaudeau, Co-Founder CEO & Dr. Anthony Bradley, Co-Founder CSO of Dalton Therapeutics.

The BioHub - by Avetix · Oct 22, 2026

Dalton TX leaders discuss building an AI operating system for drug discovery, moving beyond benchmarks to deliver real clinical impact.

Active learning compounds outperform one-shot AI drug design

Anthony Bradley points out that AI should not be expected to design a drug candidate in a single molecule. Instead, algorithms far outperform human intuition by selecting batches of compounds that maximize data learning over time. This disciplined iterative cycle significantly cuts candidate timeline discovery and reduces wasted compound synthesis.

Episode 250 - Dr. Garry Pairaudeau, Co-Founder CEO & Dr. Anthony Bradley, Co-Founder CSO of Dalton Therapeutics. thumbnail

Episode 250 - Dr. Garry Pairaudeau, Co-Founder CEO & Dr. Anthony Bradley, Co-Founder CSO of Dalton Therapeutics.

The BioHub - by Avetix·a month ago

Application workflows matter more than marginal AI benchmark gains

Anthony Bradley notes that teams obsess too much over marginal R-squared or Spearman score gains on benchmarks. Real drug discovery impact comes from how models are applied rather than chasing slight metric advantages. Garry Pairaudeau adds that standalone tools yield tiny results until daily scientific workflows are fully redesigned.

Episode 250 - Dr. Garry Pairaudeau, Co-Founder CEO & Dr. Anthony Bradley, Co-Founder CSO of Dalton Therapeutics. thumbnail

Episode 250 - Dr. Garry Pairaudeau, Co-Founder CEO & Dr. Anthony Bradley, Co-Founder CSO of Dalton Therapeutics.

The BioHub - by Avetix·a month ago

Early pipeline efficiency validates AI before market approval

Anthony Bradley disputes the belief that AI drug discovery is unproven until a medicine reaches commercial approval. Advancing candidate molecules into Phase 1 or Phase 2 with fewer compounds already validates the technology. Garry Pairaudeau notes downstream clinical results depend on biological safety that affects all molecules equally.

Episode 250 - Dr. Garry Pairaudeau, Co-Founder CEO & Dr. Anthony Bradley, Co-Founder CSO of Dalton Therapeutics. thumbnail

Episode 250 - Dr. Garry Pairaudeau, Co-Founder CEO & Dr. Anthony Bradley, Co-Founder CSO of Dalton Therapeutics.

The BioHub - by Avetix·a month ago

Partnering with biotechs keeps AI drug discovery development honest

Garry Pairaudeau notes biotechs must advance molecules before funding runs out. This financial urgency forces computational teams to focus strictly on project speed rather than theoretical models. Anthony Bradley adds that serving real partners keeps developers honest, preventing them from building shiny algorithms for their own sake.

Episode 250 - Dr. Garry Pairaudeau, Co-Founder CEO & Dr. Anthony Bradley, Co-Founder CSO of Dalton Therapeutics. thumbnail

Episode 250 - Dr. Garry Pairaudeau, Co-Founder CEO & Dr. Anthony Bradley, Co-Founder CSO of Dalton Therapeutics.

The BioHub - by Avetix·a month ago

Drug discovery needs world models rather than point predictions

Garry Pairaudeau explains that isolated predictions only reveal where a molecule is now, while strategy dictates where to go next. Anthony Bradley notes drug discovery involves fuzzy intangibles that basic algorithms miss. Developing comprehensive world models captures collective reasoning, enabling scientists to design previously impossible medicines.

Episode 250 - Dr. Garry Pairaudeau, Co-Founder CEO & Dr. Anthony Bradley, Co-Founder CSO of Dalton Therapeutics. thumbnail

Episode 250 - Dr. Garry Pairaudeau, Co-Founder CEO & Dr. Anthony Bradley, Co-Founder CSO of Dalton Therapeutics.

The BioHub - by Avetix·a month ago

AI drug discovery fails without deep software engineering alignment

Anthony Bradley warns that clever algorithms fail if they are not engineered to match available hardware systems. Major computational breakthroughs happen when software engineering scales algorithms properly without creating crippling technical debt. Useful biotech tools require teams fluent in software engineering, AI, and drug discovery.

Episode 250 - Dr. Garry Pairaudeau, Co-Founder CEO & Dr. Anthony Bradley, Co-Founder CSO of Dalton Therapeutics. thumbnail

Episode 250 - Dr. Garry Pairaudeau, Co-Founder CEO & Dr. Anthony Bradley, Co-Founder CSO of Dalton Therapeutics.

The BioHub - by Avetix·a month ago